Skip to content

A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.

Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00502853
Enrollment
10
Registered
2007-07-18
Start date
2007-10-25
Completion date
2010-07-23
Last updated
2017-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

This single arm study will measure the effect of MabThera in combination with methotrexate on the progression of synovitis, the extent of bone marrow edema, and the number of erosions in the wrist and hand of patients with rheumatoid arthritis, using a new MRI technique. Patients will receive MabThera 1000mg i.v. on days 1 and 15, in combination with a stable dosage of 10-25mg/week methotrexate throughout the duration of the study. Further courses of MabThera will be provided to eligible patients. MRI will be performed 1-2 weeks before treatment initiation, and repeated 1 and 6 months after the first MabThera infusion. The anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.

Interventions

DRUGrituximab [MabThera/Rituxan]

1000mg iv on days 1 and 15

DRUGMethotrexate

10-25mg/week

Sponsors

Hoffmann-La Roche
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* adult patients, 18-75 years of age; * rheumatoid arthritis for \>=3 months and \<=10 years; * inadequate response to methotrexate (12.5-25mg/week) for \>=3 months; * evidence of erosive disease and/or clinical synovitis in a signal joint.

Exclusion criteria

* autoimmune rheumatic diseases other than RA; * surgical operations on bones/joints in 12 weeks prior to baseline visit; * concomitant treatment with biologic agents; * previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.

Design outcomes

Primary

MeasureTime frameDescription
Early Enhancement Rate (REE)Baseline, Weeks 4 and 24A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using dynamic MRI, i.e. Contrast-Enhanced Dynamic MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (rate of early enhancement - REE) and its steady state condition (relative enhancement - RE). REE per second during the first 55 seconds was calculated according to the formula REE55 = (S55-S0)/(S0x55)x100%. The REE shows the slope of the curve of contrast uptake tangential to the α angle and is steeper if inflammation is higher.
Relative Enhancement (RE) ScoreBaseline, Weeks 4 and 24A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using dynamic MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (REE) and its steady state condition (RE).
Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis ScoreBaseline, Week 4, and Week 24Extension and degree of synovitis in wrist according to RAMRIS score developed by OMERACT. Synovitis is an area in synovial compartment that shows above normal post-gadolinium enhancement of a thickness greater than width of normal synovium. Synovitis is assessed in 3 wrist regions (distal radioulnar joint; radiocarpal joint; intercarpal and carpometacarpal joints) and in each metacarpophalangeal (MCP) joint. 1st carpometacarpal joint and 1st MCP joint are not scored. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score=the sum of the individual scores (3 wrist regions \[range 0-9\] or 4 MCP joints \[range 0-12\]) for an overall range of 0-21, where 0=no damage and maximum score \[9, 12, or 21\]=most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.
OMERACT RAMRIS Bone Edema ScoreBaseline, Weeks 4 and 24Extension and degree of bone edema in the wrist according to the RAMRIS score developed by OMERACT. Bone edema is a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) is scored separately. The scale of 0-3 was based on the proportion of bone with edema, as follows: 0=no edema; 1=1 percent (%) to 33% of bone was edematous; 2 = 34%-66% of bone was edematous; and 3= 67%-100% of bone was edematous. Total bone edema score=sum of the individual scores for an overall range of 0-69, where 0=no edema and 69=most severe edema. Change in bone edema = follow-up bone edema score - baseline score.
OMERACT RAMRIS Erosion ScoreBaseline, Week 4, and Week 24MRI bone erosion measures a sharply marginated bone lesion, with correct juxta-articular localization and typical signal characteristics, which is visible in 2 planes with a cortical break seen in at least 1 plane. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) scored separately. Scale is 0-10 based on proportion of eroded bone compared to assessed bone volume (0=no erosion; 1=1%-10% of bone eroded; 2=11%-20%, etc). For long bones, assessed bone volume is from articular surface (or best estimated position if absent) to depth of 1 centimeter (cm); in carpal bones it is the whole bone. Total erosion score=sum of individual scores for an overall range of 0-230, where 0=no erosion and 230=most severe erosion. Change in erosion=Follow-up erosion score - baseline score.

Secondary

MeasureTime frameDescription
Erythrocyte Sedimentation Rate (ESR)Baseline and Weeks 4, 12, and 24ESR was determined using the Westergren method. ESR measures how fast red blood cells (erythrocytes) fall to the bottom of a fine glass tube that is filled with the participant's blood. The higher the sedimentation rate the greater the inflammation.
C-Reactive Protein (CRP)Baseline and Weeks 4, 12, and 24CRP measured by milligrams per deciliter (mg/dL). High levels of CRP are indicators of active inflammation.
Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies CountBaseline and Weeks 4, 12, and 24Anti-CCP autoantibodies count measured by units per milliliter (U/mL). The anti-CCP autoantibodies bind antigenic determinants that contain the unusual amino acid citrulline. The anti-CCP antibody is a highly specific diagnostic test of RA (though with variable sensitivity) and a marker of joint damage with high prognostic significance.
Rheumatoid Factor (RF) Immunoglobulin M (IgM) ConcentrationsBaseline and Weeks 4, 12, and 24RF IgM concentrations measured by international units per milliliter (IU/mL). RF is an antibody reacting against the fragment, crystallizable (Fc) region of IgG. Quantitative measurements have shown a prognostic value in distinguishing between progressive and non-progressive disease in early RA, a correlation with radiologically determined joint damage, and relation with clinical improvement after disease-modifying anti-rheumatic treatment.
Total Immunoglobulin (Ig) ConcentrationsBaseline and Weeks 4, 12, and 24Total Ig concentrations as measured by milligrams per milliliter (mg/mL).
Hematocrit Concentration (%)Baseline and Weeks 4, 12, and 24
Percentage of Total B-lymphocytesBaseline and Weeks 4, 12, and 24Concentration of all B-lymphocytes subtypes was assessed.
Erosion Score - Right HandBaseline and Week 24The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.
Erosion Score - Left HandBaseline and Week 24The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.
Joint Space Narrowing - Left HandBaseline and Week 24Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 x 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).
X-Rays: Right Hand Total ScoreBaseline and Week 24Right hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and scores ranged from 0 (best possible outcome) to 180 (worst possible outcome).
Joint Space Narrowing - Right HandBaseline and Week 24Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 times \[x\] 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).
X-Rays: Left Hand Total ScoreBaseline and Week 24Left hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and ranged from 0 (best possible outcome) to 180 (worst possible outcome).
Ritchie Articular Index ScoresBaseline and Weeks 4, 12, and 24The Ritchie Articular Index is a graded assessment of tenderness in 26 joint regions. The sum of the grades of tenderness (0=not tender, 1=tender, 2=tender and causes wince, and 3 tender, causes wince and effort to withdraw) elicited by applying firm pressure over the joint margin of articular joints (such as shoulders, elbow, wrists, hips). The scores ranged from 0 (no tenderness) to 78 (most severe tenderness).
Health Assessment Questionnaire - Disability Index (HAQ-DI) ScoreBaseline and Weeks 4, 12, and 24The Stanford HAQ-DI is a participant-reported questionnaire specific for rheumatoid arthritis (RA). It consist of 20 items referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item within a domain was scored on a 4-point Likert scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. The highest score reported by the participant for a domain determined the score for that domain. The overall disability index is computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Patient's Global Assessment of PainBaseline and Weeks 4, 12, and 24The participant's assessment of their current level of pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line was described as no pain and the right-hand as unbearable pain. The participant was asked to mark the line corresponding to their current level of pain and the distance from the left edge was recorded.
DAS28 ScoreBaseline and Weeks 4, 12, and 24DAS28 calculated from the number of swollen joints and tender joints using the 28-joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hr\]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. A DAS28 score of less than or equal to (≤) 3.2 = low disease activity, a DAS28 score of \>3.2 to 5.1 = moderate to high disease activity.

Countries

Italy

Participant flow

Participants by arm

ArmCount
Rituximab + MTX
Participants received rituximab 1000 mg IV and methylprednisolone 100 mg IV on Days 1 and 15 and MTX at a stable dose of 10-25 mg/week by mouth or parenterally. Nonresponsive participants (defined as DAS28-CRP score of \>2.6) could have received additional infusions of rituximab 1000 mg (2 infusions, 14 days apart) provided a minimum of 24 weeks had passed since the first infusion of the last course of study medication.
10
Total10

Baseline characteristics

CharacteristicRituximab + MTX
Age, Continuous52.42 years
STANDARD_DEVIATION 15.681
Sex: Female, Male
Female
6 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
10 / 10
serious
Total, serious adverse events
2 / 10

Outcome results

Primary

Early Enhancement Rate (REE)

A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using dynamic MRI, i.e. Contrast-Enhanced Dynamic MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (rate of early enhancement - REE) and its steady state condition (relative enhancement - RE). REE per second during the first 55 seconds was calculated according to the formula REE55 = (S55-S0)/(S0x55)x100%. The REE shows the slope of the curve of contrast uptake tangential to the α angle and is steeper if inflammation is higher.

Time frame: Baseline, Weeks 4 and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXEarly Enhancement Rate (REE)Baseline0.356 percent per secondStandard Deviation 0.2651
Rituximab + MTXEarly Enhancement Rate (REE)Week 40.489 percent per secondStandard Deviation 0.511
Rituximab + MTXEarly Enhancement Rate (REE)Change at Week 40.150 percent per secondStandard Deviation 0.4106
Rituximab + MTXEarly Enhancement Rate (REE)Week 240.363 percent per secondStandard Deviation 0.2615
Rituximab + MTXEarly Enhancement Rate (REE)Change at Week 24-0.012 percent per secondStandard Deviation 0.3227
Comparison: Change from Baseline at Week 4p-value: 0.3358Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.9158Student's t-test
Comparison: Trend over timep-value: 0.8877Random coefficient model
Primary

OMERACT RAMRIS Bone Edema Score

Extension and degree of bone edema in the wrist according to the RAMRIS score developed by OMERACT. Bone edema is a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) is scored separately. The scale of 0-3 was based on the proportion of bone with edema, as follows: 0=no edema; 1=1 percent (%) to 33% of bone was edematous; 2 = 34%-66% of bone was edematous; and 3= 67%-100% of bone was edematous. Total bone edema score=sum of the individual scores for an overall range of 0-69, where 0=no edema and 69=most severe edema. Change in bone edema = follow-up bone edema score - baseline score.

Time frame: Baseline, Weeks 4 and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXOMERACT RAMRIS Bone Edema ScoreBaseline23.2 units on a scaleStandard Deviation 13.56
Rituximab + MTXOMERACT RAMRIS Bone Edema ScoreWeek 423.8 units on a scaleStandard Deviation 15.68
Rituximab + MTXOMERACT RAMRIS Bone Edema ScoreChange at Week 40.6 units on a scaleStandard Deviation 14.52
Rituximab + MTXOMERACT RAMRIS Bone Edema ScoreWeek 2424.0 units on a scaleStandard Deviation 14.66
Rituximab + MTXOMERACT RAMRIS Bone Edema ScoreChange at Week 240.8 units on a scaleStandard Deviation 16.77
Comparison: Change from Baseline to Week 4p-value: 0.8989Student's t-test
Comparison: Change from Baseline to Week 24p-value: 0.8834Student's t-test
Comparison: Trend over timep-value: 0.8841Random coefficient model
Primary

OMERACT RAMRIS Erosion Score

MRI bone erosion measures a sharply marginated bone lesion, with correct juxta-articular localization and typical signal characteristics, which is visible in 2 planes with a cortical break seen in at least 1 plane. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) scored separately. Scale is 0-10 based on proportion of eroded bone compared to assessed bone volume (0=no erosion; 1=1%-10% of bone eroded; 2=11%-20%, etc). For long bones, assessed bone volume is from articular surface (or best estimated position if absent) to depth of 1 centimeter (cm); in carpal bones it is the whole bone. Total erosion score=sum of individual scores for an overall range of 0-230, where 0=no erosion and 230=most severe erosion. Change in erosion=Follow-up erosion score - baseline score.

Time frame: Baseline, Week 4, and Week 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXOMERACT RAMRIS Erosion ScoreBaseline7.9 units on a scaleStandard Deviation 3.67
Rituximab + MTXOMERACT RAMRIS Erosion ScoreWeek 48.1 units on a scaleStandard Deviation 3.63
Rituximab + MTXOMERACT RAMRIS Erosion ScoreChange at Week 40.2 units on a scaleStandard Deviation 1.14
Rituximab + MTXOMERACT RAMRIS Erosion ScoreWeek 249.1 units on a scaleStandard Deviation 4.38
Rituximab + MTXOMERACT RAMRIS Erosion ScoreChange at Week 241.2 units on a scaleStandard Deviation 2.39
Comparison: Change from Baseline to Week 4p-value: 0.5911Student's t-test
Comparison: Change from Baseline to Week 24p-value: 0.1475Student's t-test
Comparison: Trend over timep-value: 0.1463Random coefficient model
Primary

Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score

Extension and degree of synovitis in wrist according to RAMRIS score developed by OMERACT. Synovitis is an area in synovial compartment that shows above normal post-gadolinium enhancement of a thickness greater than width of normal synovium. Synovitis is assessed in 3 wrist regions (distal radioulnar joint; radiocarpal joint; intercarpal and carpometacarpal joints) and in each metacarpophalangeal (MCP) joint. 1st carpometacarpal joint and 1st MCP joint are not scored. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score=the sum of the individual scores (3 wrist regions \[range 0-9\] or 4 MCP joints \[range 0-12\]) for an overall range of 0-21, where 0=no damage and maximum score \[9, 12, or 21\]=most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.

Time frame: Baseline, Week 4, and Week 24

Population: The Safety Population included all participants who received any portion of the rituximab dose and was used for efficacy and safety analyses.

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXOutcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis ScoreBaseline3.4 units on a scaleStandard Deviation 1.58
Rituximab + MTXOutcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis ScoreWeek 42.3 units on a scaleStandard Deviation 2.75
Rituximab + MTXOutcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis ScoreChange at Week 4-1.1 units on a scaleStandard Deviation 2.38
Rituximab + MTXOutcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis ScoreWeek 242.4 units on a scaleStandard Deviation 1.74
Rituximab + MTXOutcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis ScoreChange at Week 24-1.0 units on a scaleStandard Deviation 1.73
Comparison: Change from Baseline to Week 4p-value: 0.1776Student's t-test
Comparison: Change from Baseline to Week 24p-value: 0.1215Student's t-test
Comparison: Trend over timep-value: 0.2246Random coefficient model
Primary

Relative Enhancement (RE) Score

A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using dynamic MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (REE) and its steady state condition (RE).

Time frame: Baseline, Weeks 4 and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXRelative Enhancement (RE) ScoreBaseline66.978 percentStandard Deviation 42.3981
Rituximab + MTXRelative Enhancement (RE) ScoreWeek 457.889 percentStandard Deviation 51.9276
Rituximab + MTXRelative Enhancement (RE) ScoreChange at Week 4-3.812 percentStandard Deviation 34.3034
Rituximab + MTXRelative Enhancement (RE) ScoreWeek 2440.075 percentStandard Deviation 21.6891
Rituximab + MTXRelative Enhancement (RE) ScoreChange at Week 24-34.450 percentStandard Deviation 32.9609
Comparison: Change from Baseline at Week 4p-value: 0.7624Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.0212Student's t-test
Comparison: Trend over timep-value: 0.0712Random coefficient model
Secondary

Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count

Anti-CCP autoantibodies count measured by units per milliliter (U/mL). The anti-CCP autoantibodies bind antigenic determinants that contain the unusual amino acid citrulline. The anti-CCP antibody is a highly specific diagnostic test of RA (though with variable sensitivity) and a marker of joint damage with high prognostic significance.

Time frame: Baseline and Weeks 4, 12, and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXAnti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies CountBaseline55.230 U/mLStandard Deviation 33.3902
Rituximab + MTXAnti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies CountWeek 444.311 U/mLStandard Deviation 28.4448
Rituximab + MTXAnti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies CountChange at Week 4-10.133 U/mLStandard Deviation 18.0815
Rituximab + MTXAnti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies CountWeek 1241.925 U/mLStandard Deviation 32.2708
Rituximab + MTXAnti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies CountChange at Week 12-12.862 U/mLStandard Deviation 16.7306
Rituximab + MTXAnti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies CountWeek 24122.230 U/mLStandard Deviation 247.7763
Rituximab + MTXAnti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies CountChange at Week 2467.000 U/mLStandard Deviation 247.0019
Comparison: Change from Baseline at Week 4p-value: 0.1312Student's t-test
Comparison: Change from Baseline at Week 12p-value: 0.0662Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.4133Student's t-test
Comparison: Trend over timep-value: 0.6049Random coefficient model
Secondary

C-Reactive Protein (CRP)

CRP measured by milligrams per deciliter (mg/dL). High levels of CRP are indicators of active inflammation.

Time frame: Baseline and Weeks 4, 12, and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXC-Reactive Protein (CRP)Baseline21.630 mg/dLStandard Deviation 24.1805
Rituximab + MTXC-Reactive Protein (CRP)Week 423.480 mg/dLStandard Deviation 22.7518
Rituximab + MTXC-Reactive Protein (CRP)Change at Week 41.850 mg/dLStandard Deviation 16.9261
Rituximab + MTXC-Reactive Protein (CRP)Week 1210.929 mg/dLStandard Deviation 12.2432
Rituximab + MTXC-Reactive Protein (CRP)Change at Week 12-10.929 mg/dLStandard Deviation 18.1919
Rituximab + MTXC-Reactive Protein (CRP)Week 2423.410 mg/dLStandard Deviation 26.8998
Rituximab + MTXC-Reactive Protein (CRP)Change at Week 241.780 mg/dLStandard Deviation 36.7504
Comparison: Change from Baseline at Week 4p-value: 0.7376Student's t-test
Comparison: Change from Baseline at Week 12p-value: 0.1631Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.8816Student's t-test
Comparison: Trend over timep-value: 0.8835Random coefficient model
Secondary

DAS28 Score

DAS28 calculated from the number of swollen joints and tender joints using the 28-joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hr\]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. A DAS28 score of less than or equal to (≤) 3.2 = low disease activity, a DAS28 score of \>3.2 to 5.1 = moderate to high disease activity.

Time frame: Baseline and Weeks 4, 12, and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXDAS28 ScoreBaseline5.735 units on a scaleStandard Deviation 0.8099
Rituximab + MTXDAS28 ScoreWeek 45.261 units on a scaleStandard Deviation 1.5552
Rituximab + MTXDAS28 ScoreChange at Week 4-0.474 units on a scaleStandard Deviation 0.925
Rituximab + MTXDAS28 ScoreWeek 124.307 units on a scaleStandard Deviation 1.4552
Rituximab + MTXDAS28 ScoreChange at Week 12-1.587 units on a scaleStandard Deviation 0.9743
Rituximab + MTXDAS28 ScoreWeek 244.400 units on a scaleStandard Deviation 1.4263
Rituximab + MTXDAS28 ScoreChange at Week 24-1.335 units on a scaleStandard Deviation 1.1425
Comparison: Change from Baseline at Week 4p-value: 0.1396Student's t-test
Comparison: Change from Baseline at Week 12p-value: 0.005Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.005Student's t-test
Comparison: Trend over timep-value: 0.0054Random coefficient model
Secondary

Erosion Score - Left Hand

The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.

Time frame: Baseline and Week 24

Population: Safety Population; n=number of participants with values for analysis at the specified timepoints.

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXErosion Score - Left HandBaseline (n=10)1.90 units on a scaleStandard Deviation 2.558
Rituximab + MTXErosion Score - Left HandWeek 24 (n=8)1.75 units on a scaleStandard Deviation 2.619
Rituximab + MTXErosion Score - Left HandChange at Week 24 (n=8)0.00 units on a scaleStandard Deviation 0.707
Comparison: Change from Baseline at Week 24p-value: 1Student's t-test
Secondary

Erosion Score - Right Hand

The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.

Time frame: Baseline and Week 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXErosion Score - Right HandBaseline2.50 units on a scaleStandard Deviation 2.972
Rituximab + MTXErosion Score - Right HandWeek 242.19 units on a scaleStandard Deviation 2.963
Rituximab + MTXErosion Score - Right HandChange at Week 24-0.44 units on a scaleStandard Deviation 1.741
Comparison: Change from Baseline at Week 24p-value: 0.5002Student's t-test
Secondary

Erythrocyte Sedimentation Rate (ESR)

ESR was determined using the Westergren method. ESR measures how fast red blood cells (erythrocytes) fall to the bottom of a fine glass tube that is filled with the participant's blood. The higher the sedimentation rate the greater the inflammation.

Time frame: Baseline and Weeks 4, 12, and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXErythrocyte Sedimentation Rate (ESR)Baseline72.6 mm/hrStandard Deviation 27.56
Rituximab + MTXErythrocyte Sedimentation Rate (ESR)Week 463.8 mm/hrStandard Deviation 26.63
Rituximab + MTXErythrocyte Sedimentation Rate (ESR)Change at Week 4-15.6 mm/hrStandard Deviation 15.61
Rituximab + MTXErythrocyte Sedimentation Rate (ESR)Week 1248.0 mm/hrStandard Deviation 26.12
Rituximab + MTXErythrocyte Sedimentation Rate (ESR)Change at Week 12-30.2 mm/hrStandard Deviation 26.47
Rituximab + MTXErythrocyte Sedimentation Rate (ESR)Week 2453.4 mm/hrStandard Deviation 18.34
Rituximab + MTXErythrocyte Sedimentation Rate (ESR)Change at Week 24-19.1 mm/hrStandard Deviation 21.25
Comparison: Change from Baseline at Week 4p-value: 0.0254Student's t-test
Comparison: Change from Baseline at Week 12p-value: 0.0384Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.0271Student's t-test
Comparison: Trend over timep-value: 0.0124Random coefficient model
Secondary

Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

The Stanford HAQ-DI is a participant-reported questionnaire specific for rheumatoid arthritis (RA). It consist of 20 items referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item within a domain was scored on a 4-point Likert scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. The highest score reported by the participant for a domain determined the score for that domain. The overall disability index is computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame: Baseline and Weeks 4, 12, and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXHealth Assessment Questionnaire - Disability Index (HAQ-DI) ScoreBaseline1.788 units on a scaleStandard Deviation 0.6848
Rituximab + MTXHealth Assessment Questionnaire - Disability Index (HAQ-DI) ScoreWeek 41.471 units on a scaleStandard Deviation 0.7976
Rituximab + MTXHealth Assessment Questionnaire - Disability Index (HAQ-DI) ScoreChange at Week 4-0.316 units on a scaleStandard Deviation 0.3687
Rituximab + MTXHealth Assessment Questionnaire - Disability Index (HAQ-DI) ScoreWeek 120.838 units on a scaleStandard Deviation 0.6668
Rituximab + MTXHealth Assessment Questionnaire - Disability Index (HAQ-DI) ScoreChange at Week 12-0.950 units on a scaleStandard Deviation 0.7997
Rituximab + MTXHealth Assessment Questionnaire - Disability Index (HAQ-DI) ScoreWeek 240.888 units on a scaleStandard Deviation 0.7008
Rituximab + MTXHealth Assessment Questionnaire - Disability Index (HAQ-DI) ScoreChange at Week 24-0.900 units on a scaleStandard Deviation 0.6503
Comparison: Change from Baseline at Week 4p-value: 0.024Student's t-test
Comparison: Change from Baseline at Week 12p-value: 0.0045Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.0018Student's t-test
Comparison: Trend over timep-value: 0.0019Random Coefficient Model
Secondary

Hematocrit Concentration (%)

Time frame: Baseline and Weeks 4, 12, and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXHematocrit Concentration (%)Baseline36.110 percentageStandard Deviation 2.2218
Rituximab + MTXHematocrit Concentration (%)Week 437.860 percentageStandard Deviation 1.4315
Rituximab + MTXHematocrit Concentration (%)Change at Week 41.750 percentageStandard Deviation 2.9497
Rituximab + MTXHematocrit Concentration (%)Week 1237.512 percentageStandard Deviation 2.5798
Rituximab + MTXHematocrit Concentration (%)Change at Week 121.350 percentageStandard Deviation 4.3065
Rituximab + MTXHematocrit Concentration (%)Week 2437.967 percentageStandard Deviation 2.6106
Rituximab + MTXHematocrit Concentration (%)Change at Week 241.667 percentageStandard Deviation 3.6695
Comparison: Change from Baseline at Week 4p-value: 0.0934Student's t-test
Comparison: Change from Baseline at Week 12p-value: 0.4047Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.2101Student's t-test
Comparison: Trend over timep-value: 0.1451Random coefficient model
Secondary

Joint Space Narrowing - Left Hand

Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 x 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).

Time frame: Baseline and Week 24

Population: Safety Population; only participants with values at both Baseline and Week 24 were included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXJoint Space Narrowing - Left HandBaseline8.45 units on a scaleStandard Deviation 6.039
Rituximab + MTXJoint Space Narrowing - Left HandWeek 249.13 units on a scaleStandard Deviation 6.004
Rituximab + MTXJoint Space Narrowing - Left HandChange at Week 242.19 units on a scaleStandard Deviation 5.694
Comparison: Change from Baseline at Week 24p-value: 0.3132Student's t-test
Secondary

Joint Space Narrowing - Right Hand

Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 times \[x\] 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).

Time frame: Baseline and Week 24

Population: Safety Population; only participants with values at both Baseline and Week 24 were included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXJoint Space Narrowing - Right HandBaseline10.40 units on a scaleStandard Deviation 7.859
Rituximab + MTXJoint Space Narrowing - Right HandWeek 2410.13 units on a scaleStandard Deviation 6.786
Rituximab + MTXJoint Space Narrowing - Right HandChange at Week 240.94 units on a scaleStandard Deviation 6.609
Comparison: Change from Baseline at Week 24p-value: 0.7002Student's t-test
Secondary

Patient's Global Assessment of Pain

The participant's assessment of their current level of pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line was described as no pain and the right-hand as unbearable pain. The participant was asked to mark the line corresponding to their current level of pain and the distance from the left edge was recorded.

Time frame: Baseline and Weeks 4, 12, and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXPatient's Global Assessment of PainBaseline60.6 mmStandard Deviation 22.75
Rituximab + MTXPatient's Global Assessment of PainWeek 449.0 mmStandard Deviation 31.73
Rituximab + MTXPatient's Global Assessment of PainChange at Week 4-11.6 mmStandard Deviation 20.38
Rituximab + MTXPatient's Global Assessment of PainWeek 1234.7 mmStandard Deviation 16.77
Rituximab + MTXPatient's Global Assessment of PainChange at Week 12-29.9 mmStandard Deviation 28.27
Rituximab + MTXPatient's Global Assessment of PainWeek 2422.7 mmStandard Deviation 16.92
Rituximab + MTXPatient's Global Assessment of PainChange at Week 24-30.7 mmStandard Deviation 23.69
Comparison: Trend over timep-value: 0.0074Random Coefficient Model
Comparison: Change from Baseline at Week 4p-value: 0.1273Student's t-test
Comparison: Change from Baseline at Week 12p-value: 0.0132Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.1542Student's t-test
Secondary

Percentage of Total B-lymphocytes

Concentration of all B-lymphocytes subtypes was assessed.

Time frame: Baseline and Weeks 4, 12, and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXPercentage of Total B-lymphocytesBaseline24.040 percentage of cellsStandard Deviation 10.2954
Rituximab + MTXPercentage of Total B-lymphocytesWeek 422.430 percentage of cellsStandard Deviation 8.0601
Rituximab + MTXPercentage of Total B-lymphocytesChange at Week 4-1.610 percentage of cellsStandard Deviation 7.1818
Rituximab + MTXPercentage of Total B-lymphocytesWeek 1230.125 percentage of cellsStandard Deviation 12.0576
Rituximab + MTXPercentage of Total B-lymphocytesChange at Week 125.562 percentage of cellsStandard Deviation 11.6748
Rituximab + MTXPercentage of Total B-lymphocytesWeek 2424.133 percentage of cellsStandard Deviation 10.2802
Rituximab + MTXPercentage of Total B-lymphocytesChange at Week 241.111 percentage of cellsStandard Deviation 7.7194
Comparison: Change from Baseline at Week 4p-value: 0.4963Student's t-test
Comparison: Change from Baseline at Week 12p-value: 0.2198Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.6773Student's t-test
Comparison: Trend over timep-value: 0.5531Random coefficient model
Secondary

Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations

RF IgM concentrations measured by international units per milliliter (IU/mL). RF is an antibody reacting against the fragment, crystallizable (Fc) region of IgG. Quantitative measurements have shown a prognostic value in distinguishing between progressive and non-progressive disease in early RA, a correlation with radiologically determined joint damage, and relation with clinical improvement after disease-modifying anti-rheumatic treatment.

Time frame: Baseline and Weeks 4, 12, and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXRheumatoid Factor (RF) Immunoglobulin M (IgM) ConcentrationsBaseline570.922 IU/mLStandard Deviation 827.09
Rituximab + MTXRheumatoid Factor (RF) Immunoglobulin M (IgM) ConcentrationsWeek 4307.300 IU/mLStandard Deviation 337.955
Rituximab + MTXRheumatoid Factor (RF) Immunoglobulin M (IgM) ConcentrationsChange at Week 4-285.138 IU/mLStandard Deviation 530.8209
Rituximab + MTXRheumatoid Factor (RF) Immunoglobulin M (IgM) ConcentrationsWeek 12241.756 IU/mLStandard Deviation 357.8067
Rituximab + MTXRheumatoid Factor (RF) Immunoglobulin M (IgM) ConcentrationsChange at Week 12-329.167 IU/mLStandard Deviation 499.0426
Rituximab + MTXRheumatoid Factor (RF) Immunoglobulin M (IgM) ConcentrationsWeek 24281.230 IU/mLStandard Deviation 337.6633
Rituximab + MTXRheumatoid Factor (RF) Immunoglobulin M (IgM) ConcentrationsChange at Week 24-267.389 IU/mLStandard Deviation 529.7928
Comparison: Change from Baseline at Week 4p-value: 0.1725Student's t-test
Comparison: Change from Baseline at Week 12p-value: 0.0832Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.1685Student's t-test
Comparison: Trend over timep-value: 0.1331Random coefficient model
Secondary

Ritchie Articular Index Scores

The Ritchie Articular Index is a graded assessment of tenderness in 26 joint regions. The sum of the grades of tenderness (0=not tender, 1=tender, 2=tender and causes wince, and 3 tender, causes wince and effort to withdraw) elicited by applying firm pressure over the joint margin of articular joints (such as shoulders, elbow, wrists, hips). The scores ranged from 0 (no tenderness) to 78 (most severe tenderness).

Time frame: Baseline and Weeks 4, 12, and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXRitchie Articular Index ScoresChange at Week 12-11.2 units on a scaleStandard Deviation 6.11
Rituximab + MTXRitchie Articular Index ScoresBaseline20.7 units on a scaleStandard Deviation 8.3
Rituximab + MTXRitchie Articular Index ScoresWeek 416.9 units on a scaleStandard Deviation 9.49
Rituximab + MTXRitchie Articular Index ScoresChange at Week 4-3.8 units on a scaleStandard Deviation 6.78
Rituximab + MTXRitchie Articular Index ScoresWeek 129.5 units on a scaleStandard Deviation 6.72
Rituximab + MTXRitchie Articular Index ScoresWeek 2411.7 units on a scaleStandard Deviation 9.6
Rituximab + MTXRitchie Articular Index ScoresChange at Week 24-9.0 units on a scaleStandard Deviation 6.5
Comparison: Change from Baseline at Week 4p-value: 0.1101Student's t-test
Comparison: Change from Baseline at Week 12p-value: 0.0003Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.0018Student's t-test
Comparison: Trend over timep-value: 0.0023Random coefficient model
Secondary

Total Immunoglobulin (Ig) Concentrations

Total Ig concentrations as measured by milligrams per milliliter (mg/mL).

Time frame: Baseline and Weeks 4, 12, and 24

Population: Safety Population

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXTotal Immunoglobulin (Ig) ConcentrationsBaseline20.258 mg/mLStandard Deviation 6.7055
Rituximab + MTXTotal Immunoglobulin (Ig) ConcentrationsWeek 417.786 mg/mLStandard Deviation 4.7033
Rituximab + MTXTotal Immunoglobulin (Ig) ConcentrationsChange at Week 4-1.602 mg/mLStandard Deviation 3.6846
Rituximab + MTXTotal Immunoglobulin (Ig) ConcentrationsWeek 1217.296 mg/mLStandard Deviation 4.1845
Rituximab + MTXTotal Immunoglobulin (Ig) ConcentrationsChange at Week 12-2.336 mg/mLStandard Deviation 4.0998
Rituximab + MTXTotal Immunoglobulin (Ig) ConcentrationsWeek 2418.354 mg/mLStandard Deviation 4.3432
Rituximab + MTXTotal Immunoglobulin (Ig) ConcentrationsChange at Week 24-1.042 mg/mLStandard Deviation 4.5527
Comparison: Change from Baseline at Week 4p-value: 0.2938Student's t-test
Comparison: Change from Baseline at Week 12p-value: 0.2216Student's t-test
Comparison: Change from Baseline at Week 24p-value: 0.567Student's t-test
Secondary

X-Rays: Left Hand Total Score

Left hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and ranged from 0 (best possible outcome) to 180 (worst possible outcome).

Time frame: Baseline and Week 24

Population: Safety Population; only participants with values at both Baseline and Week 24 were included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXX-Rays: Left Hand Total ScoreBaseline10.35 units on a scaleStandard Deviation 7.192
Rituximab + MTXX-Rays: Left Hand Total ScoreWeek 2410.88 units on a scaleStandard Deviation 6.813
Rituximab + MTXX-Rays: Left Hand Total ScoreChange at Week 242.19 units on a scaleStandard Deviation 6.341
Comparison: Change from Baseline at Week 24p-value: 0.3617Student's t-test
Secondary

X-Rays: Right Hand Total Score

Right hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and scores ranged from 0 (best possible outcome) to 180 (worst possible outcome).

Time frame: Baseline and Week 24

Population: Safety Population; only participants with values at both Baseline and Week 24 were included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
Rituximab + MTXX-Rays: Right Hand Total ScoreBaseline12.90 units on a scaleStandard Deviation 9.433
Rituximab + MTXX-Rays: Right Hand Total ScoreWeek 2412.31 units on a scaleStandard Deviation 7.828
Rituximab + MTXX-Rays: Right Hand Total ScoreChange at Week 240.50 units on a scaleStandard Deviation 7.714
Comparison: Change from Baseline at Week 24p-value: 0.8597Student's t-test

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026